PHIBRO ANIMAL HEALTH CORP (PAHC)
Every FINRA and SEC series the site collects for PHIBRO ANIMAL HEALTH CORP: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
1.2M
Short interest
settlement 2026-08-14
7.3
Days to cover
+3.3% vs prior
49.8%
Short share of volume
2026-09-11
47
Fails to deliver
settlement 2026-08-12
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in PAHC is 1,233,227 shares, up 14,782 shares over the last month. Over the last 48 readings it ranged from 387,351 shares (15 October 2024) to 1,246,682 shares (15 April 2026). The latest reading sits at the top of that range. At the reported average volume of 170K shares a day that is 7.3 days to cover, elevated.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/pahc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 1,233,227 | +3.3% | 169,708 | 7.27 |
| 2026-07-31 | 1,193,479 | -2.0% | 212,386 | 5.62 |
| 2026-07-15 | 1,218,445 | +0.1% | 320,282 | 3.80 |
| 2026-06-30 | 1,217,323 | -1.0% | 287,446 | 4.23 |
| 2026-06-15 | 1,229,844 | +11.6% | 355,556 | 3.46 |
| 2026-05-29 | 1,101,911 | -6.5% | 357,582 | 3.08 |
| 2026-05-15 | 1,179,063 | -3.0% | 584,068 | 2.02 |
| 2026-04-30 | 1,215,037 | -2.5% | 236,559 | 5.14 |
| 2026-04-15 | 1,246,682 | +6.7% | 284,743 | 4.38 |
| 2026-03-31 | 1,168,777 | -2.5% | 351,754 | 3.32 |
| 2026-03-13 | 1,198,831 | +10.3% | 254,274 | 4.71 |
| 2026-02-27 | 1,086,791 | +1.5% | 219,975 | 4.94 |
| 2026-02-13 | 1,070,396 | +1.5% | 406,397 | 2.63 |
| 2026-01-30 | 1,054,464 | -1.2% | 185,119 | 5.70 |
| 2026-01-15 | 1,067,217 | +11.8% | 193,166 | 5.52 |
| 2025-12-31 | 954,331 | +5.2% | 284,606 | 3.35 |
| 2025-12-15 | 907,186 | +1.8% | 279,383 | 3.25 |
| 2025-11-28 | 891,226 | -3.0% | 309,756 | 2.88 |
| 2025-11-14 | 919,138 | -1.1% | 374,185 | 2.46 |
| 2025-10-31 | 929,598 | -3.8% | 251,796 | 3.69 |
| 2025-10-15 | 966,217 | +10.6% | 229,922 | 4.20 |
| 2025-09-30 | 873,352 | +3.8% | 285,456 | 3.06 |
| 2025-09-15 | 841,577 | -9.6% | 411,628 | 2.04 |
| 2025-08-29 | 931,181 | -15.1% | 388,378 | 2.40 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of PAHC volume is 49.8%, down 11.5 points over the last five sessions. Over the last 52 readings it ranged from 26.5% (13 July 2026) to 75.2% (2 July 2026). The latest reading is 9.0 points below the 30-session average of 58.8%, on 70K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 35K | 70K | 49.8% | 0 |
| 2026-09-10 | 33K | 56K | 58.9% | 0 |
| 2026-09-09 | 32K | 49K | 65.5% | 0 |
| 2026-09-08 | 37K | 56K | 66.4% | 0 |
| 2026-09-04 | 30K | 72K | 41.6% | 0 |
| 2026-09-03 | 38K | 62K | 61.3% | 0 |
| 2026-09-02 | 71K | 95K | 74.1% | 0 |
| 2026-09-01 | 89K | 169K | 53.0% | 0 |
| 2026-08-31 | 64K | 88K | 72.7% | 0 |
| 2026-08-28 | 72K | 123K | 58.3% | 0 |
| 2026-08-27 | 99K | 150K | 66.4% | 0 |
| 2026-08-26 | 63K | 108K | 58.9% | 447 |
| 2026-08-25 | 38K | 96K | 39.4% | 0 |
| 2026-08-24 | 31K | 56K | 54.8% | 0 |
| 2026-08-21 | 36K | 60K | 59.9% | 0 |
| 2026-08-20 | 29K | 56K | 51.5% | 0 |
| 2026-08-19 | 43K | 66K | 64.9% | 0 |
| 2026-08-18 | 17K | 28K | 60.1% | 0 |
| 2026-08-17 | 32K | 50K | 63.7% | 0 |
| 2026-08-14 | 19K | 28K | 68.8% | 0 |
| 2026-08-13 | 20K | 41K | 48.9% | 0 |
| 2026-08-12 | 21K | 36K | 58.3% | 0 |
| 2026-08-11 | 25K | 34K | 73.1% | 0 |
| 2026-08-10 | 45K | 63K | 71.5% | 360 |
| 2026-08-07 | 39K | 91K | 42.6% | 0 |
| 2026-08-06 | 29K | 54K | 54.1% | 0 |
| 2026-08-05 | 25K | 46K | 54.9% | 0 |
| 2026-08-04 | 31K | 60K | 50.6% | 0 |
| 2026-08-03 | 93K | 130K | 71.2% | 0 |
| 2026-07-31 | 37K | 77K | 47.3% | 0 |
Fails to deliver
SEC, by settlement date. JSONAs of 12 August 2026, the fails-to-deliver balance in PAHC is 47 shares, down 180 shares over the last settlement date. Over the last 31 readings it ranged from 1 share (8 January 2026) to 20,960 shares (15 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-12 | 47 | $34.08 | $2K |
| 2026-08-11 | 227 | $34.15 | $8K |
| 2026-08-06 | 99 | $36.01 | $4K |
| 2026-07-22 | 566 | $33.86 | $19K |
| 2026-07-17 | 346 | $34.52 | $12K |
| 2026-07-16 | 51 | $33.74 | $2K |
| 2026-07-15 | 20,960 | $33.04 | $693K |
| 2026-07-14 | 17,766 | $33.00 | $586K |
| 2026-06-15 | 442 | $31.53 | $14K |
| 2026-06-09 | 293 | $31.76 | $9K |
| 2026-06-08 | 263 | $32.43 | $9K |
| 2026-06-05 | 34 | $33.04 | $1K |
| 2026-06-02 | 1,742 | $29.87 | $52K |
| 2026-04-01 | 28 | $55.31 | $2K |
| 2026-03-25 | 10 | $55.48 | $555 |
| 2026-03-23 | 302 | $50.76 | $15K |
| 2026-03-17 | 200 | $51.17 | $10K |
| 2026-03-04 | 378 | $52.27 | $20K |
| 2026-02-24 | 1 | $51.52 | $52 |
| 2026-02-23 | 98 | $52.80 | $5K |
| 2026-02-20 | 2,266 | $51.85 | $117K |
| 2026-02-10 | 1,640 | $51.85 | $85K |
| 2026-01-21 | 36 | $41.08 | $1K |
| 2026-01-08 | 1 | $39.43 | $39 |
| 2025-12-22 | 2,590 | $37.25 | $96K |
| 2025-11-24 | 200 | $41.63 | $8K |
| 2025-11-12 | 46 | $45.33 | $2K |
| 2025-10-16 | 22 | $39.14 | $861 |
| 2025-10-06 | 58 | $38.32 | $2K |
| 2025-09-03 | 37 | $36.69 | $1K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for PAHC in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: Rodriguez Patrick (VP Finance and Treasurer) on 2026-08-06.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Rodriguez Patrick | VP Finance and Treasurer | Grant | 2K | $0.00 | $0 | 2K |
| 2026-08-06 | Weinstein Judith | See Remarks | Grant | 2K | $0.00 | $0 | 5K |
| 2026-08-06 | Miller Larry Lee | Chief Operating Officer | Grant | 4K | $0.00 | $0 | 38K |
| 2026-08-06 | Escudero Lisa Ann | See Remarks | Grant | 2K | $0.00 | $0 | 3K |
| 2026-08-06 | David Glenn | Chief Financial Officer | Grant | 3K | $0.00 | $0 | 55K |
| 2026-08-06 | Bendheim Daniel M | President and CEO | Grant | 12K | $0.00 | $0 | 15K |
| 2026-08-06 | BENDHEIM Jonathan | n/a | Grant | 3K | $0.00 | $0 | 6K |
| 2026-08-06 | BENDHEIM JACK | Executive Chairman | Grant | 12K | $0.00 | $0 | 27K |
| 2026-08-04 | Weinstein Judith | See Remarks | J | 472 | $36.60 | $17K | 3K |
| 2026-08-04 | Miller Larry Lee | Chief Operating Officer | J | 635 | $36.60 | $23K | 35K |
| 2026-08-04 | Escudero Lisa Ann | See Remarks | J | 265 | $36.60 | $10K | 2K |
| 2026-08-04 | David Glenn | Chief Financial Officer | J | 840 | $36.60 | $31K | 51K |
| 2026-08-04 | Bendheim Daniel M | President and CEO | J | 486 | $36.60 | $18K | 3K |
| 2026-08-04 | BENDHEIM JACK | Executive Chairman | J | 2K | $36.60 | $84K | 15K |
| 2026-05-29 | CORCORAN E THOMAS | n/a | Buy | 10K | $31.77 | $318K | 41K |
| 2026-05-07 | BENDHEIM JACK | President and CEO | Sell | 2K | $49.19 | $100K | 56K |
| 2026-05-07 | BENDHEIM JACK | President and CEO | Sell | 1K | $48.31 | $56K | 58K |
| 2026-05-07 | BENDHEIM JACK | President and CEO | Sell | 1K | $47.59 | $64K | 59K |
| 2026-05-06 | BENDHEIM JACK | President and CEO | Sell | 1K | $58.13 | $82K | 61K |
| 2026-05-06 | BENDHEIM JACK | President and CEO | Sell | 6K | $57.18 | $322K | 62K |
| 2026-05-05 | BENDHEIM JACK | President and CEO | Sell | 776 | $56.37 | $44K | 68K |
| 2026-05-05 | BENDHEIM JACK | President and CEO | Sell | 6K | $55.73 | $349K | 68K |
| 2026-04-30 | BENDHEIM JACK | President and CEO | Sell | 1K | $53.32 | $66K | 75K |
| 2026-04-30 | BENDHEIM JACK | President and CEO | Sell | 6K | $52.65 | $306K | 76K |
| 2026-04-29 | BENDHEIM JACK | President and CEO | Sell | 3K | $53.21 | $162K | 82K |
| 2026-04-29 | BENDHEIM JACK | President and CEO | Sell | 4K | $52.70 | $211K | 85K |
| 2026-04-28 | BENDHEIM JACK | President and CEO | Sell | 797 | $56.69 | $45K | 89K |
| 2026-04-28 | BENDHEIM JACK | President and CEO | Sell | 5K | $56.06 | $257K | 90K |
| 2026-04-28 | BENDHEIM JACK | President and CEO | Sell | 2K | $55.10 | $91K | 94K |
| 2026-04-23 | BENDHEIM JACK | President and CEO | Sell | 421 | $54.56 | $23K | 96K |
| 2026-04-23 | BENDHEIM JACK | President and CEO | Sell | 7K | $54.07 | $358K | 96K |
| 2026-04-22 | BENDHEIM JACK | President and CEO | Sell | 7K | $54.29 | $382K | 103K |
| 2026-04-21 | BENDHEIM JACK | President and CEO | Sell | 5K | $56.17 | $304K | 110K |
| 2026-04-21 | BENDHEIM JACK | President and CEO | Sell | 2K | $55.35 | $90K | 115K |
| 2026-04-16 | BENDHEIM JACK | President and CEO | Sell | 2K | $54.88 | $102K | 117K |
| 2026-04-16 | BENDHEIM JACK | President and CEO | Sell | 5K | $54.56 | $283K | 119K |
| 2026-04-16 | BENDHEIM JACK | President and CEO | Conversion | 100K | $0.00 | $0 | 124K |
| 2026-04-15 | BENDHEIM JACK | President and CEO | Sell | 799 | $58.11 | $46K | 24K |
| 2026-04-15 | BENDHEIM JACK | President and CEO | Sell | 4K | $57.21 | $207K | 25K |
| 2026-04-15 | BENDHEIM JACK | President and CEO | Sell | 3K | $56.27 | $148K | 28K |
| 2026-04-14 | BENDHEIM JACK | President and CEO | Sell | 492 | $59.69 | $29K | 31K |
| 2026-04-14 | BENDHEIM JACK | President and CEO | Sell | 7K | $59.03 | $387K | 32K |
| 2026-03-31 | BENDHEIM JACK | President and CEO | Sell | 431 | $54.35 | $23K | 38K |
| 2026-03-31 | BENDHEIM JACK | President and CEO | Sell | 7K | $53.87 | $356K | 39K |
| 2026-03-30 | BENDHEIM JACK | President and CEO | Sell | 617 | $54.31 | $34K | 45K |
| 2026-03-30 | BENDHEIM JACK | President and CEO | Sell | 6K | $53.54 | $344K | 46K |
| 2026-03-26 | BENDHEIM JACK | President and CEO | Sell | 280 | $57.17 | $16K | 52K |
| 2026-03-26 | BENDHEIM JACK | President and CEO | Sell | 7K | $56.79 | $384K | 52K |
| 2026-03-25 | BENDHEIM JACK | President and CEO | Sell | 552 | $56.86 | $31K | 59K |
| 2026-03-25 | BENDHEIM JACK | President and CEO | Sell | 5K | $56.00 | $275K | 60K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON6 Form 144 notices on file for PAHC worth $183K at the prices reported; 6 in the last 90 days worth $183K. Latest: Weinstein Judith filed on 2026-08-04 to sell 472 shares ($17K) from 2026-08-04.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-04 | Weinstein JudithOfficer | 472 | $17K | 0.002% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-08-04 | Miller Larry LeeOfficer | 635 | $23K | 0.003% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-08-04 | Escudero Lisa AnnOfficer | 265 | $10K | 0.001% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-08-04 | David GlennOfficer | 840 | $31K | 0.004% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-08-04 | Bendheim Daniel MOfficer, Director | 486 | $18K | 0.002% | 2026-08-04 | Fidelity Brokerage Services LLC |
| 2026-08-04 | BENDHEIM JACKOfficer, Director | 2K | $84K | 0.011% | 2026-08-04 | Fidelity Brokerage Services LLC |
13F holders
Tracked managers holding PAHC at their latest 13F. JSON6 of the 30 tracked managers held PAHC at their latest 13F, $48.6M in total at quarter-end prices. Millennium Management is the largest at $29.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 937K | $29.4M | 0.01% | new or n/a |
| Renaissance Technologies | 2026-06-30 | 481K | $15.1M | 0.02% | -96K |
| AQR Capital Management | 2026-06-30 | 64K | $2.0M | 0.00% | +7K |
| D. E. Shaw & Co. | 2026-06-30 | 27K | $856K | 0.00% | +19K |
| Citadel Advisors | 2026-06-30 | 23K | $719K | 0.00% | +19K |
| Two Sigma Investments | 2026-06-30 | 17K | $543K | 0.00% | -4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q4 2026 (quarter ended 2026-06-30) PHIBRO ANIMAL HEALTH CORP reported revenue of $396.7M, up 4.8% from the same quarter a year earlier, and net income of $21.7M. In FY 2026 it generated $69.0M of operating cash flow and spent $19.5M on dividends.
- Cash
- $61.4M
- Equity
- $385.5M
- Total assets
- $1.50B
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q4 2026derived | 2026-06-30 | $396.7M | $21.7M | 5.5% | n/a |
| Q1 2026 | 2026-03-31 | $383.5M | $24.0M | 6.3% | 0.59 |
| Q4 2025 | 2025-12-31 | $373.9M | $27.5M | 7.3% | 0.67 |
| Q3 2025 | 2025-09-30 | $363.9M | $26.5M | 7.3% | 0.65 |
| Q4 2025derived | 2025-06-30 | $378.7M | $17.2M | 4.5% | n/a |
| Q1 2025 | 2025-03-31 | $347.8M | $20.9M | 6.0% | 0.51 |
| Q4 2024 | 2024-12-31 | $309.3M | $3.2M | 1.0% | 0.08 |
| Q3 2024 | 2024-09-30 | $260.4M | $7.0M | 2.7% | 0.17 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2026 | 2026-06-30 | $1.52B | $99.7M | $69.0M | n/a | n/a | $19.5M |
| FY 2025 | 2025-06-30 | $1.30B | $48.3M | $80.1M | n/a | n/a | $19.4M |
| FY 2024 | 2024-06-30 | $1.02B | $2.4M | $87.6M | n/a | n/a | $19.4M |
| FY 2023 | 2023-06-30 | $977.9M | $32.6M | $13.3M | n/a | n/a | $19.4M |
| FY 2022 | 2022-06-30 | $942.3M | $49.2M | $31.6M | n/a | n/a | $19.4M |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30.
What this page is
PHIBRO ANIMAL HEALTH CORP in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows PHIBRO ANIMAL HEALTH CORP (PAHC), SEC CIK 1069899, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-12.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-08-04.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-06.JSON and CSV
- Company record
- EDGAR filing index for CIK 1069899Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- LLYELI LILLY & Co
- ALNYALNYLAM PHARMACEUTICALS, INC.
- PTCTPTC THERAPEUTICS, INC.
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- ONCBeOne Medicines Ltd.
- IONSIONIS PHARMACEUTICALS INC
- INSMINSMED Inc
- CORTCORCEPT THERAPEUTICS INC
- ROIVRoivant Sciences Ltd.
- BBIOBridgeBio Pharma, Inc.
- CYTKCYTOKINETICS INC
- LGNDLIGAND PHARMACEUTICALS INC
- VRTXVERTEX PHARMACEUTICALS INC / MA
- LQDALiquidia Corp
- SIONSionna Therapeutics, Inc.
- JAZZJazz Pharmaceuticals plc
- BLTEBELITE BIO, INC
- TVTXTravere Therapeutics, Inc.
- ARQTArcutis Biotherapeutics, Inc.
- NATRNATURES SUNSHINE PRODUCTS INC
- HOWLWerewolf Therapeutics, Inc.
- JNJJOHNSON & JOHNSON
Datasets
Frequently Asked Questions
How much of PAHC is sold short?
What is PAHC's daily short volume?
Does PAHC have fails to deliver?
Are PAHC insiders buying or selling?
Have PAHC insiders filed to sell?
What did PAHC report last quarter?
Which funds hold PAHC?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.